About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Longitudinal Study of Biomarkers | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01595126

Longitudinal Study of Biomarkers

Biomarkers are small molecules that can be detected in the body fluids of patients; they often correlate with the presence of a cancer. MicroRNAs and proteins are small molecules which have recently b...

Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Age

0 - 21 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients ages 1 day to 21 years
•Patients with radiographically and/or histologically confirmed CNS tumors treated at Children's Memorial Hospital and Lurie Children's Hospital in Chicago
•Patients must be newly diagnosed and have had no prior anticancer therapy (except surgery) for their current diagnosis. The use of steroids is permissible.
•Patients and/or parents/legal guardians must have signed an informed consent and assent when applicable.

Exclusion Criteria

•Patients who have completed treatment and do not require routine blood draws and/or lumbar punctures
•Patients who are considered too ill to participate as determined by their treating physician
•Patients who are pregnant or lactating

Related studies

RECRUITINGPhase 1/2

A Study of Mirdametinib in People With Central Nervous System Tumors

NCT07539441 · Central Nervous System Tumors, Glioma

Somatic Mosaicism in Twins Discordant for Childhood Cancer

NCT06054295 · Pediatric Central Nervous System Tumor, Central Nervous System Tumor, and more

RECRUITINGPhase 1

Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors

NCT03988283 · Pediatric Recurrent Central Nervous System Tumors

Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

NCT02530658 · Solid, Liquid, Central Nervous System Tumors

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090 · Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 19, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment100

Start dateDec 2011

Last updatedFeb 19, 2025

Condition

Central Nervous System Tumor

Locations shown

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 19, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions